Individualizing Initial HCV Therapy

Led by Tram T. Tran, MD, a panel of experts discusses their approach to individualizing initial HCV therapy based on key disease and patient characteristics that have an impact on treatment choice, including HCV genotype, race, cirrhosis, comorbidities, and comedications.
Kristen Marks, MD
Nancy Reau, MD
Norah Terrault, MD, MPH
Tram T. Tran, MD
Released: July 12, 2017 Expiration: No longer available for credit

Related Content

CCO downloadable slides from Dr. Tatyana Kushner providing insights on updated guidance for HCV screening and management in women of childbearing age

Tatyana Kushner, MD, MSCE Released: January 8, 2021

CCO module by Dr. Mark Sulkowski on optimal HCV management in PWID, children, liver transplant recipients and patients with renal disease or HIV

Stefan Zeuzem, MD
Program Director
Mark S. Sulkowski, MD
Released: December 28, 2020

CCO commentary from Paul Y. Kwo, MD, on new HBV treatment and management data presented at AASLD 2020 Virtual

Paul Y. Kwo, MD Released: December 21, 2020

Download free expert-authored slides on improving hepatitis C care by simplifying the HCV care continuum and expanding the HCV provider pool.

Stacey Trooskin, MD, PhD
Program Director
Nancy Reau, MD
Released: December 10, 2020
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grants provided by
Bristol-Myers Squibb
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.